Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Processor, cervical cytology slide, automated

PMA Number: P970018 · 2024-09-06

ApplicantBd Diagnostic Systems
Decision Date2024-09-06
PMA NumberP970018
Product CodeMKQ
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteePA

Device Summary

Processor, cervical cytology slide, automated is the device name listed in this FDA 510(k) record. The listed applicant is Bd Diagnostic Systems. It received FDA 510(k) clearance on 2024-09-06. The device is classified under product code MKQ. It was reviewed by the PA advisory panel.

Frequently Asked Questions

What is the Processor, cervical cytology slide, automated?

Processor, cervical cytology slide, automated is a medical device that received FDA 510(k) clearance on 2024-09-06. The listed applicant is Bd Diagnostic Systems.

When did Processor, cervical cytology slide, automated receive FDA 510(k) clearance?

The clearance date for Processor, cervical cytology slide, automated can be found in the official FDA records.

Who is the listed applicant for Processor, cervical cytology slide, automated?

The FDA 510(k) record lists Bd Diagnostic Systems as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Processor, cervical cytology slide, automated?

The FDA product code for Processor, cervical cytology slide, automated is MKQ.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑